Table 2.
Category | Test Type | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Prevalence (%) | Ref. |
---|---|---|---|---|---|---|---|
Protein analysis | Total protein ≥8 g/dl | 57 | 64 | 76 | 43 | 67 | 138, 143a |
Gamma-globulin ≥2.5 g/dl | 70 | 86 | 90 | 61 | 65 | 143 | |
A:G ratio | |||||||
≤0.8 | 80 | 82 | 92 | 61 | 72 | 143 | |
<0.45 | 25 | 98 | 64 | 90 | 13 | 139 | |
Protein electrophoresis | 38 | 50 | 60 | 29 | 67 | 144 | |
α1-Acid glycoprotein levels >1.5 | 85 | 100 | 100 | 75 | 70 | 192 | |
Effusion analysis | Total protein >3.5 g/dl | 87 | 60 | 77 | 71 | 72 | 142 |
Gamma-globulin ≥1.0 g/dl | 82 | 83 | 84 | 80 | 53 | 143 | |
A:G ratio | |||||||
≤0.9 | 86 | 74 | 79 | 82 | 53 | 143 | |
≤0.5 | 62 | 89 | 86 | 68 | 53 | 143 | |
Rivalta test | 98 | 80 | 84 | 97 | 51 | 143 | |
Presence of antibodies | 86 | 85 | 86 | 85 | 51 | 143 | |
Cytology suggestive of FIP | 90 | 71 | 89 | 73 | 72 | 142 | |
Antigen staining in macrophages | 72 | 100 | 100 | 68 | 62 | 142, 143, 193a | |
Serology | IFA (any titer) | 85 | 57 | 44 | 90 | 28 | 143 |
IFA (titer >1,600) | 67 | 98 | 94 | 88 | 28 | 143 | |
ELISA | 100 | 93 | 94 | 100 | 53 | 155, 187,a | |
Antigen–antibody complex | 48 | 91 | 67 | 84 | 26 | 143 | |
Viral nucleic acid detection | Nested RT-PCR | ||||||
Serum | 55 | 88 | 90 | 48 | 67 | 143, 163,a | |
Effusion | 96 | 92 | 96 | 92 | 63 | 143, 162, 163,a | |
mRNA RT-PCR | |||||||
Blood | 94 | 92 | 67 | 92 | 15 | 168, 169, 170,a |
Abbreviations: A:G ratio, albumin to globulin ratio; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescent antibody assay; mRNA, messenger RNA; NPV, negative predictive value; PPV, positive predictive value; RT-PCR, reverse transcriptase polymerase chain reaction.
Calculated based on concatenated data from original studies.